University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository

Enrolling by invitation

Conditions studied: Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma

In brief

Aim 1: To develop a prospective tissue and blood biorepository from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) presenting to UNC hospitals for routine care upper endoscopy for their condition. Aim 2: To collect clinical data from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) that includes demographic data, endoscopic procedure data, and pathology data. Aim 3: To integrate Aim 1 and 2 in a manner that will provide an efficient bi-directional flow of clinical information and specimens between laboratory and clinical scientists in order to foster innovative translational research. Aim 4: To create a biorepository for future Institutional Review Board (IRB) approved studies that have tissue and/or blood specimen component.

Key facts

Study ID

NCT02427269

Run by

University of North Carolina, Chapel Hill

People needed

1000

Starts

2015-04-28

Expected to finish

2028-05-01

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female aged 18 and older.
• Able to read, comprehend, and complete the informed consent form.
• Presenting to UNC hospitals for routine care upper endoscopy for their condition.
• Meet one of the following:
• Current or previous diagnosis of Barrett's Esophagus (BE) with or without dysplasia OR
• Current or previous diagnosis of esophageal cancer (including esophageal adenocarcinoma, intramucosal carcinoma, and squamous cell carcinoma)
• Willing to undergo biopsy and blood collection for research purposes.

You may not qualify if…

• Unable to read or understand English.
• Current incarceration.
• Current use of blood thinners such as coumadin, warfarin, clopidogrel, heparin and/or low molecular weight heparin (requires discontinuation of medication 5 days prior to and 6 days after esophagogastroduodenoscopy [EGD] and/or ensuring blood thinners have been stopped within an appropriate time frame for that specific agent and in accordance with standard clinical practice).
• Known bleeding disorder.

Where it is running

• UNC Chapel Hill — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.